Global Single-cell Omics Market Could Be Worth $1.6B by 2022

January 09, 2018

WELLESLEY, Mass., Jan. 09, 2018 – Single-cell omics analysis technologies are emerging as new force in the life science research, pharmaceutical and diagnostics industries. Critical for analyzing complex, heterogeneous biological systems, omics are used in the fight against cancer, where they are used to analyze individual cells within tumors, and are helping the development of biological drugs, according to a report by BCC Research.

The single-cell omics market is anticipated to expand at a compound annual growth rate (CAGR) of 23.5% through 2022, when its worldwide value could total nearly $1.6 billion, according to the report Single-cell Omics: Emerging Technologies and Markets.

Growth is anticipated to be robust as single-cell omics provide unique insights into cells and biological systems, and their increasing use in a wide range of markets will provide companies that can offer innovative solutions robust growth opportunities.

Companies mentioned in this report include Ambry Genetics, Berry Genomics, Cell Microsystems, DNA Electronics, Epic Sciences, Fluxion Biosciences, GE Healthcare, Illumina, Laboratory Corporation of America, Merck, Nanocellect Biomedical, Pacific Biosciences and Resolution Bioscience, among others.

Research Highlights

  • Clinical applications of single-cell omics will lead the market, with an anticipated CAGR of 76.9% though 2022, when value could reach $514.9 million.
  • Nonclinical applications include research, drug discovery and development, and applied; together, these applications will total $525.6 million by 2022, and will expand at a CAGR of 15.5% through the period.
  • Market segments forecast to have high growth include immunology (17.8% CAGR), oncology (17.1%) and microbiology (15.3%). Growth in these markets will be influenced by the development and availability of single cell analysis tools for scientific research.

“The clinical market segment has a high forecasted growth rate due to applications related to preimplantation genetic screening—a procedure that helps identify genetic defects within embryos—and liquid biopsy diagnostics, which use circulating tumor cells as biomarkers,” said John Bergin, BCC Research Analyst and report author. “A key growth driver for oncology applications is the growing recognition that cancer tumors are heterogeneous and changing over the course of a therapy. This puts a premium on understanding the genotype of individual cells within a tumor and monitoring how this changes during treatment.”

Single-cell Omics Diagnostics Focuses on Cancer

Single cell diagnostics are becoming particularly important in cancer research. The oncology diagnostics market is forecast to have a CAGR of 96.2% between 2017 and 2022, when the market could be worth $346.1 million, according to the report. Single cell assays are important for understanding the cell’s role in proliferation and for studying cancer stem cells. Applications include the capture and analysis of circulating tumor cells for screening, monitoring and therapy guidance. Currently, there are more than 20 companies specializing in the capture and detection of circulating tumor cells, many of which have developed lab tests.

Editors/reporters requesting analyst interviews should contact

Single-cell Omics: Emerging Technologies and Markets( BIO143B )
Publish Date: Dec 2017    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.